Desmopressin — Complete Research Guide (2026)

Last updated 2026-06-30

What is Desmopressin?

Desmopressin (DDAVP) is a synthetic analogue of the antidiuretic hormone arginine vasopressin that selectively activates the V2 receptor. It is approved for central (cranial) diabetes insipidus, primary nocturnal enuresis, nocturia due to nocturnal polyuria, and for controlling bleeding in mild haemophilia A and type 1 von Willebrand disease.

Its efficacy across these indications is supported by randomized trials, Cochrane systematic reviews and decades of clinical use.

This is informational content about an approved medicine and is not medical advice.

How does Desmopressin work?

Desmopressin activates renal V2 receptors in the collecting ducts to increase water reabsorption, concentrating urine and reducing urine volume, with little of vasopressin's V1 blood-pressure effect.

At higher doses it also triggers release of factor VIII and von Willebrand factor from vascular endothelial stores, transiently improving haemostasis. [INFOGRAPHIC: Desmopressin V2-receptor antidiuresis]

What does the research say about Desmopressin?

• In a Cochrane review of 47 randomized trials (3448 children), desmopressin reduced bedwetting during treatment, with the 20 ug dose giving about 1.3 fewer wet nights per week than placebo. ^[1]
• In a randomized, double-blind, placebo-controlled trial, desmopressin orally disintegrating tablet significantly reduced the number of nocturnal voids and lengthened the first undisturbed sleep period versus placebo. ^[2]
• Desmopressin transiently raises plasma factor VIII and von Willebrand factor several-fold, controlling bleeding in mild haemophilia A and type 1 von Willebrand disease without blood-product transfusion. ^[4]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

• [1] Desmopressin for nocturnal enuresis in children — Glazener CM et al., Cochrane Database Syst Rev 2002. (Cochrane review (47 RCTs, 3448 children))
• [2] Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double-blind, placebo-controlled trial — Weiss JP et al., Neurourol Urodyn 2012. (RCT (double-blind, placebo-controlled))
• [3] Low-dose desmopressin combined with serum sodium monitoring can prevent clinically significant hyponatraemia in patients treated for nocturia — Juul KV et al., BJU Int 2017. (pooled trial-data analysis)
• [4] Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years — Mannucci PM et al., Blood 1997. (clinical review)
• [5] Efficacy and safety of desmopressin orally disintegrating tablet in patients with central diabetes insipidus: results of a multicenter open-label dose-titration study — Arima H et al., Endocr J 2013. (multicenter open-label dose-titration study)

Dosing context

Approved products differ by indication and route (oral tablets, orally disintegrating sublingual tablets, intranasal spray and injection), with much lower doses used for antidiuresis than for haemostasis, and gender-specific low doses (for example 25 ug for women and 50 ug for men) approved for nocturia to limit hyponatraemia.

These are approved-product parameters described for context only and are not personal dosing advice.

Side effects & safety profile

The principal risk is dilutional hyponatraemia from water retention, which can cause headache, nausea, seizures and, rarely, death; risk rises with excess fluid intake, higher doses, older age and impaired kidney function.

The FDA restricted intranasal desmopressin for primary nocturnal enuresis because of reports of severe hyponatraemia and seizures, and fluid restriction plus serum-sodium monitoring are advised across indications.

Stacking & combinations

In refractory nocturnal enuresis desmopressin is sometimes combined with an anticholinergic under specialist supervision, but it is otherwise used as a single agent.

Finding Desmopressin vendors

User reviews

Frequently asked questions

References

1. [1] Desmopressin for nocturnal enuresis in children — Glazener CM et al., Cochrane Database Syst Rev 2002. PMID: 12137645. View sourceStudy: Cochrane review (47 RCTs, 3448 children)Desmopressin significantly reduced bedwetting during treatment compared with placebo.
2. [2] Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double-blind, placebo-controlled trial — Weiss JP et al., Neurourol Urodyn 2012. PMID: 22447415. View sourceStudy: RCT (double-blind, placebo-controlled)Desmopressin orally disintegrating tablet significantly reduced nocturnal voids and was well tolerated.
3. [3] Low-dose desmopressin combined with serum sodium monitoring can prevent clinically significant hyponatraemia in patients treated for nocturia — Juul KV et al., BJU Int 2017. PMID: 27862898. View sourceStudy: pooled trial-data analysisMinimum effective gender-specific dosing with serum-sodium monitoring reduced clinically significant hyponatraemia in nocturia.
4. [4] Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years — Mannucci PM et al., Blood 1997. PMID: 9326215. View sourceStudy: clinical reviewDesmopressin raises factor VIII and von Willebrand factor to treat mild haemophilia A and type 1 von Willebrand disease safely and inexpensively.
5. [5] Efficacy and safety of desmopressin orally disintegrating tablet in patients with central diabetes insipidus: results of a multicenter open-label dose-titration study — Arima H et al., Endocr J 2013. PMID: 23811987. View sourceStudy: multicenter open-label dose-titration studyDesmopressin orally disintegrating tablet provided effective, well-tolerated antidiuretic control in central diabetes insipidus.